GAM
TVRD

Gotham Asset Management’s Tvardi Therapeutics TVRD Stock Holding History

Gotham Asset Management’s Portfolio TVRD Stock Details TVRD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q3 		– Sell
-808
Closed -$448K – 1070
2017
Q2 		$448K Buy
+808
New +$513K 0.01% 769

Other funds holding TVRD

State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
RCP
Rho Capital Partners New York $20.4M AUM
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
C
Chescapmanager Baltimore, Maryland $1.12B AUM 67.49% 1-Year Est. Return
DGI
Disciplined Growth Investors Minneapolis, Minnesota $4.89B AUM 33.85% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Gotham Asset Management's TVRD Position: Q3 2017 in Review

Gotham Asset Management sold out of Tvardi Therapeutics (TVRD) in Q3 2017, closing a stake of 808 shares — an estimated $448K sold.

Gotham Asset Management first reported a position in TVRD in Q2 2017 and held it in 1 quarter. The position peaked at $448K in Q2 2017. 121 funds tracked by Wall St. Rank hold TVRD as of Q3 2017.

  • Gotham Asset Management reported no remaining Tvardi Therapeutics position as of Q3 2017 after selling out during the quarter.
  • Gotham Asset Management sold 808 Tvardi Therapeutics shares in Q3 2017, an estimated $448K.
  • Gotham Asset Management first reported a position in Tvardi Therapeutics in Q2 2017 and held it in 1 quarter.
  • Gotham Asset Management's Tvardi Therapeutics position peaked at $448K in Q2 2017.
  • 121 funds tracked by Wall St. Rank held Tvardi Therapeutics as of Q3 2017.

Based on Gotham Asset Management's 13F filing for Q3 2017, filed 14 Nov 2017.